Sign In
Buy ALGS
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
09:00am, Monday, 22'nd Jul 2024
Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
08:00am, Wednesday, 10'th Jul 2024
SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
02:30am, Wednesday, 05'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
10:56am, Tuesday, 04'th Jun 2024
Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
08:30am, Wednesday, 29'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #PFIC--Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress.
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
04:05pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutic
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
08:00am, Tuesday, 21'st May 2024
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
10:36am, Thursday, 16'th May 2024
Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
04:05pm, Tuesday, 30'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
04:05pm, Thursday, 25'th Apr 2024
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Wednesday, 27'th Mar 2024
After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
08:00am, Wednesday, 27'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Tuesday, 12'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
04:05pm, Tuesday, 05'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
08:00am, Monday, 26'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
